18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis

Nuclear Medicine and Biology

Volumn 31, Issue 2, 2004, Pages 179-189

  Chen, Xiaoyuan ^a   Park, Ryan ^a   Shahinian, Anthony H ^a   Tohme, Michel ^a   Khankaldyyan, Vazgen ^b   Bozorgzadeh, Mohammed H ^a   Bading, James R ^a   Moats, Rex ^b   Laug, Walter E ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Angiogenesis; Glioblastoma; MicroPET; Quantitative Autoradiography; RGD

Indexed keywords

BENZOIC ACID DERIVATIVE; LYSINE; N 4 FLUOROBENZOYLARGINYLGLYCYLASPARTIC ACID F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; TRACER; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; DIAGNOSTIC AGENT; FLUORINE; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BILIARY EXCRETION; BRAIN TUMOR; CANCER TRANSPLANTATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; MOUSE; MUSCLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; URINARY EXCRETION; ANIMAL; ANTIBODY SPECIFICITY; EVALUATION; FEASIBILITY STUDY; METABOLIC CLEARANCE RATE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PILOT STUDY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEASIBILITY STUDIES; FEMALE; FLUORINE RADIOISOTOPES; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGAN SPECIFICITY; PILOT PROJECTS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 12144287687     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.10.002     Document Type: Article

References (31)

1. Bader B.L., Rayburn H., Crowley D., Hynes R.O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 95:1998;507-519.
2. Belvisi L, Bernardi A, Checchia A, Manzoni K, Potenza D, Scolastico D, Castorina M, Cupelli A, Giannini G, Carminati P, Pisano C. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides, Org Lett. 3:2001;1001-1004.
3. Black P.M. Brain tumor. Part 2. N Engl J Med. 324:1991;1555-1564.
4. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Investig. 96:1995;1815-1822.
5. Buerkle M.A., Pahernik S.A., Sutter A., Jonczyk A., Messmer K., Dellian M. Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumors in vivo. Br J Cancer. 86:2002;788-795.
6. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2003;30:in press
7. Daumas-Duport C. Histological grading of gliomas. Curr Opin Neurol Neurosurg. 5:1992;924-931.
8. Davis F.G., Freels S., Grutsch J., Barlas S., Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type an analysis based on surveillance. Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 88:1998;1-10.
9. 3 integrin antagonists. J Med Chem. 42:1999;3033-3340.
10. Folkman J. Angiogenesis and angiogenesis inhibition an overview. EXS. 79:1997;1-8.
11. 3 integrin antagonists a new class of tracers for tumor targeting. J Nucl Med. 40:1999;1061-1071.
12. Haubner R., Wester H.-J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycosylated RGD-containing peptides tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 42:2001;326-336.
13. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:2001;1781-1785.
14. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62:2002;6146-6151.
15. Janssen M., Oyen W.J.G., Massuger L.F.A.G., Frielink C., Dijkgraaf I., Edwards D.S., Radjopadhye M., Corstens F.H.M., Boerman O.C. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 17:2002;641-646.
16. Jemal A.J., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J Clin. 52:2003;5-26.
17. Kilbourn M.R., Dence C.S., Welch M.J., Mathias C.J. Fluorine-18 labeling of proteins. J Nucl Med. 28:1987;462-470.
18. MacDonald T.J., Tabrizi P., Shimada H., Zlokovic B.V., Laug W.E. Detection of brain tumor invasion and micrometastasis in vivo by expression of enhanced green fluorescent protein. Neurosurgery. 43:1998;1437-1443.
19. v-integrin antagonist. Neurosurgery. 48:2001;151-157.
20. 18F]fluoro-L-DOPA. Appl Radiat Isot. 43:1992;989-996.
21. 3 integrin related tumor imaging. Nucl Med Biol. 30:2003;1-9.
22. Plate KH, Mennel HD. Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol. 47:1995;89-94.
23. Puduvalli VK, Yung AW. New frontiers in therapy of malignant gliomas. Forum. 8:1998;261-269.
24. Puduvalli V.K., Sawaya R. Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J Neurooncol. 50:2000;189-200.
25. Rooprai H.K., Vanmeter T., Panou C., Schnull S., Trillopazos G., Davies D., Pilkington G.J. The role of integrin receptors in aspects of glioma invasion in vitro. Int J Dev Neurosci. 17:1999;613-623.
26. 3 integrin for tumor targeting. Bioconjugate Chem. 13:2002;561-570.
27. Taga T., Suzuki A., Gonzalez-Gomez I., Gilles F.H., Stins M., Shimada H., Barsky L., Weinberg K.J., Laug W.E. αv-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer. 98:2002;690-697.
28. Tonn J.-C., Wunderlich S., Kerkau S., Klein C.E., Roosen K. Invasive behavior of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res. 18:1998;2599-2605.
29. 18F]fluorobenzoate. Nucl Med Biol. 19:1992;275-281.
30. Van Hagen P.M., Breeman W.A.P., Bernard H.F., Schaar M., Mooij C.M., Srinivasan A., Schmidt M.A., Krenning E.P., de Jong M. Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer. 90:2000;186-198.
31. Wester H.-J., Hamacher K., Stöcklin G. A comparative study of n. c.a. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol. 23:1996;365-372.